Investigation of Genetic Determinants of Capecitabine Toxicity.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Capecitabine (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Pharmacogenomic
- 24 Jul 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 13 Aug 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 18 Jul 2012 New source identified and integrated (Mayo Clinic).